HOMEPAGE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

VRAX — Virax Biolabs Group Limited

VRAX (Virax Biolabs Group Limited) stock: $0.59, $0.8M market cap, $4.2M cash, -$3.1M EV, $0.8M fully diluted market cap. Data from Fully Diluted's biotech stocks database.

What they do

Virax Biolabs Group Limited is a holding company incorporated as an exempted company under the laws of the Cayman Islands. As a holding company with no material operations of its own, we conduct substantially all of our operations through subsidiaries in the United Kingdom, the United States and China.

Source: 20-F FY2026 via SEC EDGAR

Share price
$0.59
Market cap
$0.8M
Cash
$4.2M
Enterprise value
-$3.1M

Balance sheet

Cash$4.2M
Debt$0.3M
Net cash$3.9M
Enterprise value-$3.1M
Basic shares1.4M shares
Fully diluted shares1.4M shares
Fully diluted market cap$0.8M
Cash per share$3.07
Quarterly burn$1.1M
Cash runway3.7 quarters

Cash figures as of 2025-03-31. Database snapshot: 2026-11-11.

Share structure

Common
0.6M
Pre-funded warrants
0.2M
Options
0.0M
RSUs
0.0M
Warrants
0.6M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
—
FDSO
1.4M

Cap table as of 2026-03-31.

Price history

Loading VRAX daily closes…

Loading price history…

Next catalyst

ViraxImmune · Est. Feb 14, 2027 · quarter midpoint · guided in 7 wks

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 718 stocks.
Subscribe to Compounding Ego